Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

doi:10.1200/PO-26-00091

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.

JCO precision oncology - 1 Jun 2026

Milewski David, Fallatah Arwa, Groff Maya, Rahmy Abdelrahman, Khan Sophia R, Okafor Christian, Glassberg Brittany, Chou Hsien-Chao, Heselmeyer-Haddad Kerstin, Wangsa Darawalee, Wangsa Danny, Kim Yong, Isanogle Kristine, Song Young, Zhang Xiaohu, Thomas Craig, Difilippantonio Simone, Park Jong-In, Wei Jun S, Hawley Robert G, Glod John, Khan Javed

Abstract excerpt

PURPOSE: Medullary thyroid carcinoma (MTC) is often driven by activating mutations in the RET receptor tyrosine kinase. Multikinase and selective inhibitors targeting RET are highly effective for RET-mutant MTC, but acquired resistance is commonly observed, limiting clinical efficacy. MATERIALS AND METHODS: We performed a comprehensive genomic and pharmacological analysis of acquired resistance in a previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperidines

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Pyridones

Share to Pyrimidinones

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42258786
DOI: 10.1200/PO-26-00091
PMCID: PMC13258109

Genes

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.PMID 42258786Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectivesSemantic proximity Read ↗

Medullary Thyroid Cancer: Molecular Biology and Novel Molecular TherapiesSemantic proximity Read ↗

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read ↗

Drug resistance profiles of mutations in the RET kinase domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.